Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012 May 01; 30(13):1534-40.

View in: PubMed

subject areas

Adenocarcinoma
Aged
Androgen Antagonists
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Hormonal
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Chi-Square Distribution
Disease-Free Survival
Double-Blind Method
Drug Resistance, Neoplasm
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Odds Ratio
Placebos
Prednisone
Prostate-Specific Antigen
Prostatic Neoplasms
Risk Assessment
Risk Factors
Taxoids
Time Factors
Treatment Outcome
United States

authors with profiles

Walter M. Stadler